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Angiom otins link F-actin architecture to Hippo 
pathw ay signaling
Sebastian M ana-Capelli, M urugan Param asivam , Shubham  Dutta, and Dannel M cCollum
Departm ent of Biochem istry and M olecular Pharm acology and Program  in Cell Dynam ics, University of M assachusetts 
M edical School, W orcester, M A 01605
ABSTRACT The Hippo pathw ay regulates the transcriptional coactivator YAP to control cell 
proliferation, organ size, and stem  cell m aintenance. M ultiple factors, such as substrate stiff-
ness, cell density, and G protein–coupled receptor signaling, regulate YAP through their ef-
fects on the F-actin cytoskeleton, although the m echanism  is not known. Here we show that 
angiom otin proteins (AM O T130, AM O TL1, and AM O TL2) connect F-actin architecture to YAP 
regulation. First, we show that angiom otins are required to relocalize YAP to the cytoplasm  
in response to various m anipulations that perturb the actin cytoskeleton. Second, angiom o-
tins associate with F-actin through a conserved F-actin–binding dom ain, and m utants defec-
tive for F-actin binding show  enhanced ability to retain YAP in the cytoplasm . Third, F-actin 
and YAP com pete for binding to AM O T130, explaining how  F-actin inhibits AM O T130-m edi-
ated cytoplasm ic retention of YAP. Furtherm ore, w e find that LATS can synergize with F-actin 
perturbations by phosphorylating free AM O T130 to keep it from  associating w ith F-actin. 
Together these results uncover a m echanism  for how F-actin levels m odulate YAP localization, 
allowing cells to m ake developm ental and proliferative decisions based on diverse inputs that 
regulate actin architecture.
IN TRO DUCTIO N
The Hippo pathway regulates contact inhibition of cell growth, cell 
proliferation, apoptosis, stem  cell m aintenance and differentiation, 
and the developm ent of cancer in m am m als and flies (Yu and Guan, 
2013). The core Hippo pathway in m am m als consists of the M ST1/2 
kinases, which activate the LATS1/2 kinases, which in turn phospho-
rylate and inhibit the hom ologous transcriptional coactivators YAP 
and TAZ (hereafter referred to as YAP), causing them  to relocalize 
from  the nucleus to the cytoplasm . Nuclear YAP prom otes growth, 
proliferation, and stem  cell m aintenance. YAP localizes to the 
nucleus in cells at low density, and at high density YAP exits the nu-
cleus and cells stop proliferation. How YAP is regulated in response 
to cell density is not known, although recent evidence suggests that 
the organization of the actin cytoskeleton contributes through an 
unknown m echanism  (Dupont et al., 2011; Fernandez et al., 2011; 
Sansores-Garcia et al., 2011; W ada et al., 2011; Zhao et al., 2012). In 
addition, G protein–coupled receptors have been shown to m odu-
late Hippo signaling through F-actin (M iller et al., 2012; M o et al., 
2012; Yu et al., 2012). F-actin can influence YAP activity through 
both Hippo pathway (LATS)–dependent (W ada et al., 2011; Zhao 
et al., 2012; Kim  et al., 2013) and Hippo pathway–independent 
m echanism s (Dupont et al., 2011; Aragona et al., 2013). Intriguingly, 
angiom otin fam ily m em bers AM O T, AM O TL1, and AM O TL2 can 
also inhibit YAP both in a Hippo pathway–independent m anner by 
binding and sequestering YAP in the cytoplasm  and by activating 
the YAP inhibitory kinase LATS (Hippo dependent; Chan et al., 2011; 
Param asivam  et al., 2011; W ang et al., 2011; Zhao et al., 2011; 
Hirate et al., 2013; Leung and Zernicka-Goetz, 2013). Given their 
ability to associate with actin structures (Ernkvist et al., 2008; Gagne 
et al., 2009), we hypothesized that angiom otins m ight m ediate the 
effects of F-actin on YAP. Here we report evidence in support of this 
hypothesis.
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localize to vesicular structures [see Discussion], as observed for 
AM O T80 [Heller et al., 2010], a shorter form  of AM O T lacking the 
actin-binding region.) In addition, a sm all fragm ent (AM O T130 resi-
dues 157–191) centered around the residues deleted in AM O T130-
AB localized to F-actin structures when fused to green fluorescent 
protein (GFP; Figure 1A).
Actin binding of AM O T130 is regulated by LATS2 kinase
O f interest, the conserved sequence block in the actin-binding re-
gion of angiom otins contains a perfect consensus LATS phospho-
rylation site (HXRXXS; serine 175 in AM O T130; Figure 1, C and D), 
suggesting that LATS m ight regulate the actin-binding properties 
of angiom otins. Consistent with this idea, expression of LATS2 (but 
not kinase-dead LATS2) could disrupt both AM O T130 localization 
to actin fibers and its actin-bundling activity (Figure 2, A–C). M uta-
tion of the putative LATS phosphorylation site in the actin-binding 
region of AM O T130 or AM O TL2 blocked in vitro phosphorylation 
of each protein by LATS2 (Supplem ental Figure S2A) and blocked 
the ability of LATS2 to inhibit the actin-bundling and localization 
activity of AM O T130 (Figure 2, A–C). In contrast, AM O T130-S175E 
could not localize to or bundle actin (Figure 2, A–C). Thus LATS2 
RESULTS
The N -term inal Hippo pathw ay regulatory dom ain 
of angiom otins contains an actin-binding m otif
O verexpression of the long isoform  of AM O T (AM O T130) causes 
form ation of large F-actin bundles that also contain AM O T130 
(Ernkvist et al., 2008; Dai et al., 2013; Figure 1A). W hen expressed 
at lower levels, AM O T130 localizes as puncta on stress fibers but 
does not cause obvious actin bundling (Figure 1B). To determ ine 
the significance of AM O T130 localization to the actin cytoskeleton, 
we sought to identify m utants defective in actin localization and 
bundling. Deletion analysis revealed that the actin localization do-
m ain was contained within an 100–am ino acid conserved stretch 
near the am ino term inus of all three angiom otin proteins (Figure 1, 
A, C, and D, and Supplem ental Figure S1A). By deleting individual 
blocks of conserved sequence within this region, we found that actin 
localization required a short m otif (e.g., AM O T130 residues 169–178; 
Figure 1, C and D). Deletion of this region in full-length AM O T130 
(AM O T130- AB; AB  actin binding; Figure 1A) or in the actin-local-
izing fragm ent of AM O TL2 (Supplem ental Figure S1A) disrupts both 
actin localization and bundling activity. (Note that the AM O T130-
AB m utant and other form s of AM O T130 that cannot bind F-actin 
FIGURE 1: AM O T130 associates with F-actin through a dom ain in its N -term inus. (A) U2O S cells were transfected with 
plasm ids for expression of M yc-tagged full-length AM O T130, am ino acids 100–200 of AM O T130 (AM O T130 (100-200)), 
AM O T130 with a deletion in the actin-binding region (AM O T130- AB), or a fragm ent containing the actin-binding 
region fused to GFP (AM O T130-(157-191)) and im aged at low densities. Cells were stained for AM O T130 using anti-M yc 
or GFP antibodies and for F-actin using phalloidin. DN A was stained with DAPI. Bar, 20 µm . (B) U2O S cells were 
transfected with a plasm id for expression of full-length M yc-tagged AM O T130 and then stained for AM O T130 (using 
anti-M yc antibodies) and endogenous m yosin IIA, which is a m arker for stress fibers. Bar, 20 µm . (C) Representation of 
angiom otin protein features, including the actin-binding region flanked by YAP-binding m otifs. (D) An alignm ent of the 
am ino-term inal region of hum an AM O T130, AM O TL1, and AM O TL2 is shown. The region containing the actin-binding 
region (underlined) and LATS phosphorylation site are indicated (box). N um bers correspond to am ino acid num bers for 
AM O T130.
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FIGURE 2: LATS2 inhibits association of AM O T130 with F-actin. (A) U2O S cells were transfected with the indicated 
AM O T130 and LATS2 plasm ids and im aged at low densities. Cells were stained for AM O T130 (M yc), F-actin using 
phalloidin, and LATS2 or LATS2-KD (FLAG). DN A was stained with DAPI. Bar, 20 µm . (B, C) Q uantification of the 
phenotypes of the cells in A. Graphs represent the average from  three experim ents (n  100 each), and error bars 
indicate SD of the averages. In all cases, brackets on top of bars represent statistical significance (Fisher test, 
p < 0.00001). (D) Im m unostaining of endogenous AM O T130, phospho-AM O T130, and actin. HEK 293T cells were 
stained with phalloidin to visualize actin and with the indicated antibodies. (E) HEK 293T cells growing at increasing 
densities were costained with anti-AM O T130 and anti–phospho-AM O T130 (p-AM O T130). DN A was stained with DAPI. 
Bar, 20 µm .
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(no AM O T130) YAP rem ained prim arily in 
the nucleus. W ild-type AM O T130 and 
AM O T130-S175A were able to cause lim -
ited translocation of YAP to the cytoplasm  
(only in cells with high AM O T130 expres-
sion levels; Figure 4C). O f interest, the 
AM O T130-S175A m utant was less effective 
than wild-type AM O T130 at bringing YAP 
to the cytoplasm . In contrast, the m utants 
that could not bind F-actin (AM O T130- AB 
or AM O T130-S175E) were m uch m ore ef-
fective at shifting YAP to the cytoplasm  
(Figure 4, A–C), and in these cases YAP colo-
calized with AM O T130 on vesicles (Figure 
4A), sim ilar to when AM O T130 was coex-
pressed with LATS2 (Supplem ental Figure 
S3A). Sim ilarly, soon after disruption of 
F-actin in HEK 293T cells using latrunculin B, 
endogenous YAP was observed to colocal-
ize with S175-phosphorylated endogenous 
AM O T130 on structures (possibly vesicles) 
near the plasm a m em brane (Figure 4D). 
W hen we assayed transcription from  a synthetic YAP-dependent 
prom oter (Dupont et al., 2011), although all form s of AM O T130 are 
expressed sim ilarly (Supplem ental Figure S3B) and show inhibition 
of YAP (probably due to overexpression), we again found that the 
AM O T130 m utants that could not bind F-actin were m ore effective 
at inhibiting YAP (Figure 4E and Supplem ental Figure S3C). Together 
these results show that F-actin binding antagonizes the ability of 
AM O T130 to inhibit YAP nuclear localization and function.
F-actin and YAP com pete for binding to AM O T130
Binding to F-actin could inhibit the ability of AM O T130 to direct YAP 
to the cytoplasm  by blocking either AM O T130 activation of LATS or 
binding of AM O T130 to YAP. To address this question, we m ade 
AM O T130 m utants that were specifically defective at either activat-
ing LATS2 or binding YAP. To disrupt interaction between AM O T130 
and YAP, we m utated the three L/PPXY m otifs in AM O T130 that are 
known to m ediate interaction between AM O T130 and the W W  do-
m ains of YAP (Chan et al., 2011; W ang et al., 2011; Zhao et al., 2011; 
Adler et al., 2013a). Because AM O T130 m utants defective at acti-
vating LATS had not been identified, we m utated blocks of con-
served residues in the am ino term inus of AM O T130, which was 
known to be required for LATS2 activation (Param asivam  et al., 
2011), and tested their ability to prom ote LATS2 phosphorylation of 
YAP. Because m utation of residues 13–27 abolished the ability of 
AM O T130 to activate LATS2 (Figure 4F), this dom ain was term ed 
the LATS activation dom ain (LAD). O f interest, both AM O T130- AB 
and wild-type AM O T130 prom oted LATS2 phosphorylation of YAP 
to a sim ilar degree, suggesting that F-actin binding m ight not regu-
late AM O T130 activation of LATS2. Next we used these m utants to 
test how F-actin regulates the ability of AM O T130 to prom ote cyto-
plasm ic localization of YAP. Expression of different versions of 
AM O T130- AB with deletions in either the YAP-binding m otifs or 
the LAD dem onstrated that the enhanced ability of AM O T130- AB 
to translocate YAP to the cytoplasm  depends m ostly on the L/PPXY 
m otifs, with the LAD m aking only a m inor contribution (Figure 4B). 
This suggests that F-actin binding prim arily interferes with AM O T130 
binding to YAP.
Because the F-actin–binding dom ain of AM O T130 is closely 
flanked by YAP-binding m otifs (Figure 1C), we hypothesized that 
F-actin and YAP m ight com pete for binding to AM O T130, which 
phosphorylation of AM O T130 inhibits its localization to F-actin. 
Localization of endogenous AM O T130 in 293T cells supported this 
conclusion. In cells at low density, AM O T130 was observed to co-
localize with actin fibers (Figure 2D). In contrast, phospho-AM O T130 
(analyzed with phospho-serine 175–specific antibodies; Hirate 
et al., 2013) did not colocalize with F-actin fibers and was instead 
observed at regions of cell–cell contact (Figure 2D). As cells be-
cam e m ore dense and established m ore cell–cell contacts, in-
creased phospho-AM O T130 staining was observed at cell–cell 
junctions (Figure 2E). Endogenous phospho-AM O T130 was only 
occasionally seen at vesicles, like the phospho-m im etic AM O T130-
S175E m utant (see Discussion).
Because the LATS phosphorylation site is in the m iddle of the 
AM O T130 actin-binding region, we hypothesized that just as phos-
phorylation inhibits AM O T130 actin binding, binding of AM O T130 
to F-actin m ight interfere with phosphorylation by LATS. To test this 
m odel in vitro, we first determ ined whether AM O T130 could bind 
directly to F-actin in vitro. Consistent with in vivo data, recom binant 
AM O T130 (Figures 3A and Supplem ental Figure S2B), but not 
AM O T130-S175E (Figure 3A), could bind to F-actin, whereas both 
AM O T130 and AM O T130-S175E bound recom binant YAP (Figure 
3B). Using in vitro kinase assays, we observed that LATS2 could 
phosphorylate AM O T130 in the absence but not in the presence of 
F-actin (Figure 3C). This result is consistent with recent observations 
showing that LATS phosphorylation of AM O T130 in vivo is enhanced 
by disruption of F-actin (Dai et al., 2013). Thus LATS m ay act, after 
perturbations that reduce F-actin levels, to phosphorylate free 
AM O T130 to keep it from  rebinding to F-actin.
Actin binding–deficient m utants of AM O T130 show  
enhanced YAP inhibition
Previous studies showing that YAP is inhibited by F-actin disruption 
could be explained if an inhibitor of YAP was kept sequestered by 
binding to F-actin. If AM O T130 functions in this m anner, then m u-
tants that cannot bind F-actin should have enhanced ability to 
inhibit YAP in vivo. Therefore we tested whether localization to 
F-actin affected the ability of AM O T130 to inhibit YAP nuclear local-
ization and transcriptional activity. W ild-type and m utant form s of 
AM O T130 were transfected into U2O S cells, and the localization of 
endogenous YAP was exam ined (Figure 4, A–C). In control cells 
FIGURE 3: LATS phosphorylation of AM O T130 prevents its association with F-actin, and 
AM O T130 binding to F-actin inhibits LATS phosphorylation. (A, B) In vitro binding assays 
between recom binant M BP-AM O T130 or M BP-AM O T130-S175E and purified nonm uscle F-actin 
(A) or recom binant GST-YAP2 (B). M BP-AM O T130 protein bound to beads was used to pull 
down (PD) F-actin or GST-YAP2. Levels of bound proteins and input are shown. (C) Kinase assays 
of recom binant M BP-AM O T130 (preincubated with or without purified nonm uscle F-actin) and 
LATS2 kinase im m unoprecipitated from  HEK293 cells. Phosphorylated AM O T130 was detected 
using a phospho-S175–specific antibody. The levels of bound proteins and input are shown.
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FIGURE 4: Actin and YAP com pete for binding to AM O T130, and AM O T130 m utants that cannot bind F-actin are m ore 
efficient at inhibiting YAP. (A, B) U2O S cells were transfected with either control plasm id or one of the indicated 
AM O T130 plasm ids. The next day, cells were stained for endogenous YAP and scored for the percent of cells with m ore 
YAP in the nucleus than the cytoplasm  (N   C), m ore in the cytoplasm  than the nucleus (C  N ), or equal signal in the 
cytoplasm  and nucleus (C  N ). (A) Exam ple im ages. (B) Average from  three experim ents (n  100 each), and the error 
bars indicate SD of the averages. Brackets on top of bars represent statistical significance (Fisher test, *p < 0.00001, 
**p < 0.02). Bar, 20 µm . (C) The AM O T130, AM O T130-S175A, AM O T130-S175E, and AM O T130- ABD expression levels 
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triple angiom otin knockdown alone (Figure 5B). The different rela-
tive effects of LATS and angiom otin knockdown after latrunculin or 
serum  starvation treatm ent could be explained if LATS and angio-
m otin respond som ewhat differently to each stim uli. Collectively 
these results show that LATS and angiom otins are m ajor m ediators 
of various inputs that act through the F-actin cytoskeleton to affect 
YAP localization.
DISCUSSIO N
The F-actin cytoskeleton is a m ajor regulator of the Hippo pathway 
target YAP, m ediating signals triggered by substrate stiffness, cell 
density, and cell detachm ent, as well as signaling from  G protein–
coupled receptors (Dupont et al., 2011; Sansores-Garcia et al., 2011; 
W ada et al., 2011; M iller et al., 2012; M o et al., 2012; Yu et al., 2012; 
Zhao et al., 2012). W e show here that angiom otin proteins connect 
F-actin organization to YAP regulation. The AM O T130 protein binds 
purified F-actin in vitro, and we observe it on stress fibers in cells. 
This fits with studies suggesting that F-actin structures that respond 
to m echanical forces such as stress fibers are involved in YAP regula-
tion (Dupont et al., 2011; W ada et al., 2011). Although we show that 
AM O T130 can bind F-actin in vitro, it will be im portant in future 
studies to determ ine whether AM O T130 can distinguish between 
types of F-actin structures in vivo. A direct com petition for binding 
to AM O T130 between F-actin and YAP appears to underlie the abil-
ity of F-actin to keep AM O T130 from  binding and sequestering YAP 
in the cytoplasm . Angiom otins are m ajor m ediators of the effects of 
F-actin on YAP, since they are required for the cytoplasm ic retention 
of YAP that occurs when F-actin is disrupted. Together these results 
suggest a m odel (Figure 5E) in which AM O T130 is sequestered on 
F-actin structures and stim uli that cause loss of these structures, 
such as increased cell density, result in release of AM O T130, allow-
ing it to bind and inhibit YAP.
This sim ple m odel m ay actually be m ore com plex. For exam ple, 
in overexpression studies, we observe that the phosphom im etic 
form  of AM O T130, which does not bind F-actin and has enhanced 
ability to keep YAP out of the nucleus, colocalizes with YAP in vesicu-
lar structures in the cytoplasm . This raises the possibility that m em -
brane/vesicular localization could play an additional role in YAP 
regulation. It is worth noting that we only observe localization of 
endogenous phospho-AM O T130 and YAP to possible vesicular 
structures soon after F-actin disruption. In other situations phospho-
AM O T130 colocalizes with YAP at cell junctions. O ne explanation 
for these results is that overexpression of AM O T130-S175E m ay 
cause accum ulation of vesicular interm ediates that would norm ally 
be sent on to the plasm a m em brane. Consistent with this notion, 
overexpression of AM O T80, a short form  of AM O T lacking the 
could allow F-actin levels to m odulate the ability of AM O T130 to 
bind to YAP. Consistent with this idea, overexpression of YAP in 
U2O S cells blocked localization of coexpressed AM O T130 to 
F-actin, and both proteins localized to vesicles (Supplem ental 
Figure S3D). W e next tested biochem ically whether F-actin and YAP 
com pete for binding to AM O T130. AM O T130 (on beads) was 
allowed to bind F-actin and then incubated in the presence or 
absence of increasing am ounts of YAP (Figure 4G). W e observed 
that high YAP concentrations displaced F-actin from  AM O T130, 
showing that YAP and actin com pete for binding to AM O T130. 
Together these data point toward com petition between F-actin and 
YAP for binding to AM O T130, which could explain how actin m odu-
lates AM O T130 regulation of YAP.
Angiom otins m ediate the effects of actin perturbation 
on YAP localization
Various treatm ents that perturb F-actin (Supplem ental Figure S4A) 
cause YAP to exit the nucleus (Dupont et al., 2011; Fernandez et al., 
2011; Sansores-Garcia et al., 2011; W ada et al., 2011; Zhao et al., 
2012). Exam ples include 1) F-actin depolym erization by latrunculin 
B or cytochalasin D; 2) serum  withdrawal, which acts through G pro-
tein–coupled receptors to affect the actin cytoskeleton (M iller et al., 
2012; M o et al., 2012; Yu et al., 2012); 3) type 2 m yosin inhibition, 
which affects F-actin stress fibers (Dupont et al., 2011); and 
4) increased cell density (Dupont et al., 2011). W e found that angio-
m otins (and LATS) are required for regulation of YAP localization in 
each case. W e used sm all interfering RNA (siRNA)/short hairpin RNA 
(shRNA) to knock down AM O T, AM O TL1, and AM O TL2 in HEK293A 
and M CF10A cells (Supplem ental Figure S4B). Although knockdown 
of individual angiom otins had lim ited effects, knockdown of all three 
caused nuclear retention of YAP and m aintenance of YAP activity 
after F-actin depolym erization, type 2 m yosin inhibition, serum  with-
drawal, and increased cell density in HEK293A and M CF10A cells 
(Figure 5, A–D, and Supplem ental Figure S4, C–F). (Note that the 
effect of triple knockdown in HEK293A cells after latrunculin B treat-
m ent or serum  starvation could be rescued by overexpression of 
AM O T130 or AM O TL2; Figure 5, A and B.) In HEK293A cells, triple 
angiom otin knockdown blocked cytoplasm ic accum ulation of YAP 
to a sim ilar degree as LATS1/2 knockdown after latrunculin B treat-
m ent but had a significantly stronger effect than LATS1/2 knock-
down after starvation (Figure 5, A and B). Com bined knockdown of 
both LATS1/2 and all three angiom otins caused an additive effect 
after latrunculin B treatm ent com pared with knockdown of LATS1/2 
or the three angiom otins alone (Figure 5A). However, after serum  
starvation, com bined LATS1/2 and triple angiom otin knockdown 
did not significantly enhance YAP nuclear retention com pared with 
in single cells were quantified and correlated with endogenous YAP localization. The graphs plot the average AM O T130 
levels for individual cells (ordered based on AM O T levels) and are scored for those with m ore YAP in the nucleus than 
cytoplasm  (N   C, solid sym bols) or not (N   C + C  N , open sym bols). (D) Endogenous YAP and phospho-AM O T130 
(p-AM O T130) staining in HEK193T cells with or without treatm ent with latrunculin B for 15 m in. DN A is stained with 
DAPI. Bar, 20 µm . (E) U2O S cells were transfected with the sam e AM O T130 plasm ids as in A, as well as with an 
8xGTIIC-luciferase YAP-dependent prom oter plasm id and a plasm id with the SV40 prom oter driving Renilla luciferase. 
The next day, cell extracts were m ade, and luciferase activity was m easured for each sam ple. The levels of firefly 
luciferase (YAP activity) were norm alized to the level of Renilla luciferase in each sam ple. Error bars indicate the SD 
between triplicates. Brackets on top of bars represent statistical significance (Student’s test, *p < 0.005, **p < 0.01). In 
all cases, the experim ents were done in triplicate, and the error bars indicate the SD of the averages. (F) LATS2, YAP, 
and the indicated AM O T130 plasm ids were transfected into HEK293 cells, and the levels of AM O T130, LATS2, YAP, and 
phospho-YAP were analyzed by W estern blotting. The experim ent was done in triplicate, and error bars indicate the SD 
of the averages. (G) Com petition between actin and YAP for binding to AM O T130. Recom binant M BP-AM O T130 
protein on beads was prebound to F-actin then incubated in the presence or absence of increasing am ounts of 
recom binant GST-YAP2. The levels of bound proteins and input are shown.
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FIGURE 5: Angiom otins and LATS are required to efficiently inhibit YAP after F-actin disturbance. (A) HEK293A cells 
were transfected with control siRN A (luciferase) or siRN A against AM O T130, AM O TL1, AM O TL2, a com bination of all 
three angiom otins (triple KD), or a com bination of LATS1 and LATS2 (LATS1+2), as indicated. To test for off-target 
effects, plasm ids for expressing either AM O T130 (R AM O T130) or AM O TL2 (R AM O TL2) were transfected the next day 
to test for rescue of the triple-knockdown phenotype. Forty-eight hours later, all cells were treated with either 
latrunculin B (see exam ple im ages) or blebbistatin (Blebb) and then fixed and stained for localization of endogenous 
YAP. Cells were scored for the percentage of cells with m ore YAP in the nucleus than the cytoplasm  (N   C), m ore in the 
cytoplasm  than the nucleus (C  N ), or equal signal in the cytoplasm  and nucleus (C  N ). Brackets on top of bars 
represent statistical significance (Fisher test, p < 0.0005). (B) HEK293A cells were m anipulated as in A, except that 
instead of drug treatm ent, cells were shifted to m edia without serum  for 2 h and then fixed and stained for endogenous 
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M ATERIALS AN D M ETHO DS
Cell culture
Hum an HEK 293, HEK293A, HeLa, and U2O S cell lines were 
grown in DM EM  (GIBCO , Grand Island, NY) supplem ented with 
10%  (vol/vol) fetal bovine serum  (GIBCO ) and 1%  (vol/vol) penicillin/
streptom ycin (Invitrogen, Grand Island, NY). Hum an m am m ary epi-
thelial M CF10A cells were cultured in M EGM  BulletKit (Lonza, 
Hopkinton, M A) with all additives except for the gentam icin–
am photericin B m ix. M edia was also com plem ented with 100 ng/m l 
cholera toxin (Sigm a-Aldrich, St. Louis, M O ) and 1%  penicillin and 
streptom ycin (Invitrogen). All cell lines were cultured in a hum idified 
incubator at 37°C with 5%  CO 2.
In vitro kinase assays and luciferase assays
For detection of LATS2-m ediated phosphorylation of angiom otins 
with P-32, HEK 293 cells were transfected in 12-well plates with 
LATS2, various angiom otin constructs, and LATS activators (M ST1, 
SAV, and M O B1), using Lipofectam ine 2000 (Invitrogen). Forty 
hours after transfection, cells were lysed in im m unoprecipitation 
buffer (50 m M  Tris-HCl, pH 7.4, 150 m M  NaCl, 1.0%  Nonidet P-40, 
2%  glycerol) supplem ented with 1  protease inhibitor cocktail 
(Sigm a-Aldrich), 100 nM  sodium  vanadate (Sigm a-Aldrich), and 
50 m M  sodium  fluoride (Sigm a-Aldrich), and lysates were cleared 
by centrifugation at 13,000 rpm  for 10 m in at 4°C. Protein lysate 
(300 µg) was processed for im m unoprecipitation as described pre-
viously (Param asivam  et al., 2011). Both LATS2 and angiom otin 
proteins were im m unoprecipitated together on the sam e beads. 
Kinase assays and W estern blotting were carried out as previously 
described (Param asivam  et al., 2011).
For kinase assays in the presence of F-actin, LATS2-FLAG  was 
transfected in HEK293 cells together with its activators, M ST1 and 
M O B1. After 24 h, LATS2 was purified in phosphate buffer using 
anti-FLAG  M 2 antibody (Sigm a-Aldrich) and m agnetic protein G 
beads (Invitrogen) following the m anufacturers’ directions. 
M altose-binding protein (M BP)–AM O T130 was expressed and 
purified as described and eluted with 20 m M  m altose in supple-
m ented actin buffer (5 m M  Tris-Cl, pH 8.0, 0.2 m M  CaCl2, 50 m M  
KCl, 2 m M  M gCl2, and 1 m M  ATP; Cytoskeleton, Denver, CO ) for 
30 m in at 4ºC. Eluted AM O T130 (10 µl, 0.5 µg) was then preincu-
bated with or without 10 µl of F-actin (see prior description, 5 µM  
final concentration) for 15 m in at room  tem perature. Control reac-
tions were taken to 20 µl with supplem ented actin buffer. For ki-
nase reactions the AM O T130/F-actin m ix was added to LATS2-
bound beads prerinsed with supplem ented actin buffer. After 
incubation at 30°C for 30 m in, kinase reactions were stopped by 
boiling in SDS sam ple buffer. Sam ples were then subjected to 
SDS–PAG E, and phospho-AM O T130 was detected by W estern 
blotting using a phosphospecific antibody.
F-actin–binding dom ain, causes accum ulation of large endosom al-
like com partm ents (Heller et al., 2010). In future studies it will be 
im portant to determ ine whether localization of AM O T130-YAP 
com plexes to vesicles and the plasm a m em brane plays a role in YAP 
regulation.
There has been som e question about the im portance of LATS for 
F-actin–dependent regulation of YAP (Dupont et al., 2011; Yu et al., 
2012; Zhao et al., 2012; Aragona et al., 2013). O ur work, together 
with other studies, suggests that LATS functions together with an-
giom otins to regulate YAP in response to F-actin perturbation. W e 
show that LATS contributes to cytoplasm ic retention of YAP after F-
actin disruption and serum  withdrawal, and several reports have 
shown that LATS becom es activated and inhibits YAP by direct 
phosphorylation when F-actin is disrupted (W ada et al., 2011; Zhao 
et al., 2012; Aragona et al., 2013). O ur work indicates that activated 
LATS can also act through angiom otins to inhibit YAP. LATS phos-
phorylation of AM O T130 is enhanced by F-actin disruption in vivo 
(Dai et al., 2013), and we show that the ability of LATS2 to phospho-
rylate AM O T130 in vitro is increased in the absence of F-actin. From  
this study, as well as from  several recent reports, it is clear that LATS 
phosphorylation of AM O T130 inhibits its ability to bind F-actin 
(Adler et al., 2013b; Chan et al., 2013; Dai et al., 2013; Hirate et al., 
2013). W e show that LATS phosphorylation blocks AM O T130 bind-
ing to F-actin, allowing it to bind YAP and sequester it in the cyto-
plasm . LATS phosphorylation of AM O T130 appears to have addi-
tional functions. A recent study indicates that AM O T130 
phosphorylation could also enhance AM O T130 binding to the W W  
dom ain–containing E3 ubiquitin ligase AIP4, which can both stabi-
lize AM O T130 and prom ote YAP degradation (Adler et al., 2013a,b). 
It rem ains to be determ ined whether AIP4, like YAP, directly com -
petes with F-actin for binding to AM O T130. Recent studies also 
suggest that AM O T130 phosphorylation by LATS could enhance 
the AM O T130–LATS interaction (Hirate et al., 2013) and have 
effects on the actin cytoskeleton (Dai et al., 2013). Thus LATS can 
prom ote cytoplasm ic localization of YAP in response to F-actin 
depolym erization by phosphorylating AM O T130 in addition to its 
well-characterized function in phosphorylating YAP (Figure 5E).
The com petition between F-actin and YAP for binding to 
AM O T130 could also provide a LATS-independent m echanism  for 
F-actin–dependent regulation of YAP. The LATS-dependent and 
-independent m echanism s could allow for com binatorial regulation 
of YAP activity based on both inputs that affect the actin cytoskeleton, 
such as cell density, and inputs that affect LATS activity, such as cell–
cell contacts (Kim  et al., 2011), as was recently suggested (Aragona 
et al., 2013). Together this work shows that F-actin, angiom otins, and 
LATS form  a regulatory m odule that controls YAP in response to di-
verse inputs such as changes in cell density, substrate stiffness, and G 
protein–coupled receptor signaling (Halder et al., 2012).
YAP. Cells were scored as in A. Exam ple im ages are shown. Brackets on top of bars represent statistical significance 
(Fisher test, *p < 0.0005, **p < 0.005). (C) Lentiviral infection was used to introduce either control shRN A (directed 
against luciferase) or shRN A against all three angiom otins (AM O T130, AM O TL1, and AM O TL2; triple knockdown) into 
M CF10A cells. Sixty hours after infection, cells were left untreated, treated with cytochalasin D (CytoD), or starved of 
serum  for an additional 12 h. Cells were then fixed and stained for endogenous YAP. YAP localization was scored as in A. 
Exam ple im ages are shown. (D) HEK293A cells were transfected twice with control or a com bination of AM O T130, 
AM O TL1, and AM O TL2 siRN A (see Materials and Methods). Cells were fixed after 72 h and stained for endogenous 
YAP. YAP localization was scored as predom inantly excluded from  the nucleus (excluded) or diffuse throughout the cell 
(diffuse). Exam ple im ages are shown. In all cases, the bar graphs represent averages from  three experim ents (n  100 
each), and the error bars indicate the SD of the averages. N uclei were visualized with DAPI. Bar, 20 µm . C, cytoplasm ; 
Kd, knockdown; N , nucleus. (E) M odel of F-actin–regulated angiom otin (AM O T) inhibition of YAP.
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assem bled as follows. First, a constant am ount of actin was incu-
bated with M BP-AM O T130 beads for 15 m in at room  tem perature. 
Then a constant volum e of either GST elution buffer or increasing 
am ounts of eluted GST-YAP2 were added as indicated in Figure 3F. 
Sam ples were then incubated for an additional 30 m in. In all cases, 
beads were washed once with phosphate buffer and boiled in SDS–
PAGE sam ple buffer. For the cosedim entation experim ent, M BP-
AM O T130 was eluted from  m altose beads with 10 m M  m altose for 
30 m in and incubated with actin as for 30 m in at room  tem perature. 
Sam ples were then centrifuged at 150,000  g in a Beckm an TLX 
bench-top ultracentrifuge for 1.5 h. Pellets were suspended in the 
sam e volum e as the supernatants and boiled in SDS–PAGE loading 
buffer. Protein sam ples were the subjected to SDS–PAGE and W est-
ern blotting with the specified antibodies.
Plasm ids
Sources for plasm ids used in this study were described previously 
(Param asivam  et al., 2011). All AM O T130, AM O TL1, and AM O TL2 
constructs were expressed from  pCDNA4-M yc-His. Large deletion 
m utants in AM O T130, AM O TL1, and AM O TL2 were constructed 
using PCR followed by subcloning. Point and sm all deletion m uta-
tions in AM O T130 and AM O TL2 were m ade using the Q uick-
Change II Site m utagenesis kit (Stratagene, Santa Clara, CA). All 
localization studies were perform ed in a 12-well form at. The various 
angiom otin plasm ids were transfected at 600 ng/well, and LATS2 
constructs (pcDNA3.1-LATS2-FLAG and pcDNA3.1-LATS2-KD-
FLAG) were transfected at 400 ng/well.
Antibodies
M ouse anti-tubulin and m ouse anti-FLAG (M 2) were purchased from  
Sigm a-Aldrich. The rabbit-anti YAP (sc15407), m ouse anti-YAP 
(sc10199), rabbit anti-M yc (sc789), m ouse anti-M yc 9E10 (sc46), 
m ouse anti-GFP (9996), m ouse anti-AM O T130 B-4 (sc-166924), and 
goat anti-AM O TL2 (82501) were from  Santa Cruz Biotechnology 
(Dallas, TX). M yosin IIa was purchased from  Cell Signaling Technol-
ogy (3403; Beverly, M A). The rabbit anti-AM O T antibody was gener-
ated by the Fernandes lab (CHUQ -CHUL Research Center, Univer-
site´ Laval, Q uebec City, Canada). Rabbit anti-AM O TL1 was provided 
by Anthony Schm itt (Pennsylvania State University, State College, 
PA). AM O T130-S175 phospho-specific antibody was from  Hiroshi 
Sasaki (Kum am oto University, Kum am oto, Japan).
siRN A/shRN A transfection
Knockdowns in HEK293A cells were perform ed using 30 nM  control 
siRNA or SM ARTpool siRNA (Dharm acon, Lafayette, CO ) and 3 µl of 
RNAiM AX Lipofectam ine (Invitrogen). Cells were cultured for 48 h 
after transfection. The only exceptions were experim ents with cells 
at high densities, for which siRNAs were transfected twice at 40 nM  
(second transfection after 24 h), and cells were fixed after 72 h of the 
first transfection. For rescuing experim ents, plasm ids for protein ex-
pression were transfected after 24 h of knockdown with Lipo-
fectam ine 2000. Silencing reagents were as follows. Control siRNA 
(firefly luciferase 5 CGUACGCGGAAUACUUCGA3 , referred to as 
GL2), AM O T SM ARTpool siRNA (targeting both AM O T80 and 
AM O T130; M -015417), AM O TL1 SM ARTpool siRNA (M -017595), 
AM O TL2 SM ARTpool siRNA (M -013232), LATS1 SM ARTpool siRNA 
(M - 004632), and LATS2 SM ARTpool siRNA (M -003865). M CF10A-
cell knockdowns were done using lentiviral infection of shRNA, and 
cells were collected after 3 d. For the studies with AM O TL2 knock-
down alone, M CF10A with integrated constructs for stably knocking 
down AM O TL2 and control (luciferase) were used (Param asivam  
et al., 2011). To generate a triple knockdown, stable AM O TL2 
Luciferase assays were perform ed in U2O S and HeLa cells 24 h 
after transfection. All transfections were perform ed in 12-well plates 
using Lipofectam ine 2000 and a com bination of 300 ng of GTIIC-
Luc (34615; Addgene, Cam bridge, M A), 20 ng of pRL-SV40P 
(referred to as renilla, 27163; Addgene), and the described 
AM O T130 plasm id (300 ng for U2O S and 25 ng for HeLa cells). Cells 
lysates were generated and reactions perform ed following direc-
tions described in the Dual Luciferase Reporter Assay System  
(Prom ega, M adison, W I).
Cell starvation and drug treatm ents
HEK293A cells were starved for 2 h in DM EM  without serum . 
M CF10A cells were starved overnight in DM EM /F12 supplem ented 
with 100 ng/m l cholera toxin (Sigm a-Aldrich) and 1%  penicillin and 
streptom ycin (Invitrogen). Latrunculin B and cytochalasin D were 
used at 1 µM  for 1 h, except for the phospho-AM O T130/YAP stain-
ing (Figure 4D), for which cells were incubated for only 15 m in. Note 
that cytochalasin D was used to disrupt F-actin in M CF10A cells be-
cause latrunculin B was too toxic in these cells. Blebbistatin was 
used at 25 µM  for 1 h.
Im m unocytochem istry
U2O S, HeLa, and M CF01A cells cultured on coverslips were fixed in 
phosphate-buffered saline (PBS)/4%  paraform aldehyde for 10 m in 
and perm eabilized/blocked with 0.1%  Triton X-100 and 5%  norm al 
goat serum  (Invitrogen) for 30 m in. Cells were subsequently 
incubated with appropriate prim ary antibodies for 1–2 h at room  
tem perature. They were washed three tim es in PBS with 0.1%  Triton 
X-100 and incubated with Alexa Fluor–conjugated secondary 
antibodies (M olecular Probes, Grand Island, NY) for 1 h at room  
tem perature. 4 ,6-Diam idino-2-phenylindole (DAPI) staining and 
Alexa-conjugated phalloidin (488 or 568; Invitrogen) were also 
added to the secondary antibody solution when appropriate. After 
three washes, coverslips were m ounted on slides using Vectashield 
(Vecta Laboratories, Burlingam e, CA) and viewed using fluorescent 
m icroscopy (Nikon Eclipse E600). Im ages were acquired using a 
cooled charge-coupled device cam era (O RCA-ER; Ham am atsu, 
Bridgewater, NJ). Im age processing and analysis were carried out 
with IPLab Spectrum  software (Signal Analytics, Vienna, VA) and 
Im ageJ software (Schneider et al., 2012).
In vitro protein-binding assays
AM O T130 and AM O T130-S175E were cloned in pDEST-M BP 
(provided by M arian W alhout’s lab) using Gateway (Invitrogen) stan-
dard procedures. M BP-AM O T130 and M BP-AM O T130-S175E were 
expressed with 1 m M  isopropyl- -d-thiogalactoside (IPTG) for 4 h at 
25°C and shaking. M BP fusion proteins were purified with m altose 
beads (NEB, Ipswich, M A) in phosphate buffer (50 m M  NaH2PO 4, 
150 m M  NaCl, 10 m M  -m ercaptoethanol, 0.1%  Triton, and 1 m M  
phenylm ethylsulfonyl fluoride) following the m anufacturer’s direc-
tions. Expression of glutathione S-transferase (GST)–YAP2 (pGEX-
5X-2 vector; GE Healthcare, Piscataway, NJ) was induced by addi-
tion of 1 m M  IPTG for 2 h at 25°C, and then GST-YAP2 was purified 
with glutathione beads (GE Healthcare) in phosphate buffer and 
eluted with 20 m M  glutathione for 30 m in. Nonm uscle actin was 
purchased as part of the Actin Binding Protein Kit (Cytoskeleton) 
and was polym erized for 1 h at 25°C following the m anufacturer’s 
directions. For the in vitro pull-down experim ents, bead-bound 
AM O T130 and AM O T130-S175E were incubated for 30 m in at room  
tem perature with eluted GST-YAP2 and/or 5 µM  F-actin in phos-
phate buffer containing 2 m M  ATP and 2 m M  M gCl2 to keep F-actin 
stable (Actin Binding Protein Kit m anual). Com petition assays were 
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knockdown cells were infected with a com bination of AM O T130 
and AM O TL1 lentiviral supernatants. At the sam e tim e, stable 
control cells were infected with control viral supernatant as a control. 
Viral supernatants were generated by the shRNA Core Facility, 
University of M assachusetts M edical School (W orcester, M A), to 
target GCCATGAGAAACAAATTGG (AM O TL1) or TGGTGGAA-
TATCTCATCTA (AM O T130).
Real-tim e quantitative PCR 
After appropriate treatm ents to cells on 6-well (M CF10A) or 12-well 
plates (HEK293A), m edia was aspirated off and cells were lysed with 
TRIzol (Life Technologies, Grand Island, NY) and processed for total 
RNA isolation according to the m anufacturer’s protocol. cDNA was 
prepared by oligo-dT (Prom ega) using SuperScript II Reverse Tran-
scriptase (Invitrogen). Real-tim e quantitative PCR was perform ed 
using KAPA SYBR Fast-M aster M ix Universal kit (Kapa Biosystem s, 
W ilm ington, M A). Target m RNA levels were m easured relative to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) m RNA lev-
els. The following prim ers were used. GAPDH-F, CTCCTGCACCAC-
CAACTGCT, and GAPDH-R, GGGCCATCCACAGTCTTCTG; CTGF-
F, AGGAGTGGGTGTGTGACGA, and CTGF-R, CCAGGCAGTTG-
GCTCTAATC; AM O T-F2, ACTACCACCACCTCCAGTCA, and 
AM O T-R2, ACAAGGTGACGACTC TCTGC; AM O TL1-F1, GCAGA-
CAGGAAAACTGAGGA, and AM O TL1-R1, AAATGTGGTGGGAA-
CAGAGA; and AM O TL2-F1, GCTACTGGGGTAGCAACTGA, and 
AM O TL2-R1, GAAGGCAGTGAGGAACTGAA. AM O T, AM O TL1, 
and AM O TL2 prim ers were ordered from  Real Tim e Prim ers (Elkins 
Park, PA).
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